Galectin Therapeutics Inc. (GALT)
Largest Insider Buys in Sector
GALT Stock Price History Chart
GALT Stock Performance
About Galectin Therapeutics Inc.
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which …
Insider Activity of Galectin Therapeutics Inc.
Over the last 12 months, insiders at Galectin Therapeutics Inc. have bought $62,897 and sold $76,500 worth of Galectin Therapeutics Inc. stock.
On average, over the past 5 years, insiders at Galectin Therapeutics Inc. have bought $54,933 and sold $217,079 worth of stock each year.
Highest buying activity among insiders over the last 12 months: FREEMAN KEVIN D (director) — $43,832. Zordani Richard A. Jr. (director) — $11,570. ELDRED KARY (director) — $4,105.
The last purchase of 500 shares for transaction amount of $1,300 was made by ELDRED KARY (director) on 2024‑10‑23.
List of Insider Buy and Sell Transactions, Galectin Therapeutics Inc.
| 2024-10-23 | director | 500 0.0008% | $2.60 | $1,300 | 0.00% | |||
| 2024-10-17 | director | 1,300 0.0021% | $2.64 | $3,432 | +3.20% | |||
| 2024-10-16 | director | 10,000 0.0164% | $2.70 | $27,000 | +3.42% | |||
| 2024-08-23 | director | 2,759 0.0044% | $2.30 | $6,346 | +17.32% | |||
| 2024-08-22 | director | 741 0.0012% | $2.30 | $1,704 | +17.32% | |||
| 2024-07-22 | director | 400 0.0006% | $2.39 | $956 | +6.05% | |||
| 2024-06-20 | director | 2,500 0.0037% | $2.38 | $5,950 | +6.61% | |||
| 2024-04-30 | director | 1,000 0.0016% | $3.52 | $3,520 | -23.43% | |||
| 2024-04-24 | President and CEO | 1,000 0.0016% | $3.39 | $3,390 | -17.93% | |||
| 2024-04-23 | Sale | 10 percent owner | 3,677 0.0054% | $3.06 | $11,252 | -20.12% | ||
| 2024-04-22 | Sale | 10 percent owner | 21,323 0.0344% | $3.06 | $65,248 | -11.31% | ||
| 2024-04-22 | director | 2,500 0.0039% | $2.98 | $7,450 | -11.31% | |||
| 2024-01-16 | director | 400 0.0008% | $2.39 | $956 | +41.21% | |||
| 2024-01-16 | director | 500 0.0008% | $1.79 | $893 | +41.21% | |||
| 2023-07-19 | director | 1,598 0.0028% | $1.79 | $2,854 | +14.62% | |||
| 2023-02-21 | 1,000 0.0017% | $1.59 | $1,591 | +10.00% | ||||
| 2023-02-16 | 1,000 0.0017% | $1.52 | $1,520 | +17.33% | ||||
| 2023-01-25 | director | 1,300 0.0022% | $1.11 | $1,443 | +60.00% | |||
| 2022-11-17 | Chief Financial Officer | 4,000 0.0065% | $1.32 | $5,280 | +22.79% | |||
| 2022-10-28 | director | 10,000 0.0171% | $1.41 | $14,100 | +16.55% |
Insider Historical Profitability
| CZIRR JAMES C | 10 percent owner | 5922207 9.436% | $2.75 | 3 | 30 | <0.0001% |
| ELDRED KARY | director | 50213 0.08% | $2.75 | 9 | 0 | +5.2% |
| FREEMAN KEVIN D | director | 34769 0.0554% | $2.75 | 28 | 0 | +0.09% |
| Zordani Richard A. Jr. | director | 32083 0.0511% | $2.75 | 6 | 0 | <0.0001% |
| LEWIS JOEL | President and CEO | 2000 0.0032% | $2.75 | 7 | 0 | <0.0001% |
Institutional Investor Ownership
| The Vanguard Group | $4.73M | 3.19 | 1.98M | +1.96% | +$90,908.42 | <0.0001 | |
| Advisor Group Holdings Inc | $3.02M | 2.04 | 1.26M | +1.1% | +$32,974.50 | 0.01 | |
| BlackRock | $1.7M | 1.15 | 712,638 | -0.38% | -$6,484.07 | <0.0001 | |
| Geode Capital Management | $1.36M | 0.91 | 567,161 | +10.25% | +$126,086.24 | <0.0001 | |
| Geneos Wealth Management Inc | $977,152.00 | 0.66 | 408,850 | -0.92% | -$9,082.00 | 0.05 |